| 1.46 -0.08 (-5.19%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.39  |
1-year : | 2.82 |
| Resists | First : | 2.05 |
Second : | 2.42 |
| Pivot price | 1.69 |
|||
| Supports | First : | 1.45 |
Second : | 1.21 |
| MAs | MA(5) : | 1.54 |
MA(20) : | 1.75 |
| MA(100) : | 1.86  |
MA(250) : | 1.65 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 9.1 |
D(3) : | 12.8 |
| RSI | RSI(14): 28.3 |
|||
| 52-week | High : | 2.59 | Low : | 1.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ INMB ] has closed above bottom band by 10.3%. Bollinger Bands are 16.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.51 - 1.52 | 1.52 - 1.53 |
| Low: | 1.44 - 1.45 | 1.45 - 1.45 |
| Close: | 1.45 - 1.46 | 1.46 - 1.47 |
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Fri, 23 Oct 2026
INmune Bio Inc. Estimates – NASDAQ:INMB - TradingView
Fri, 23 Oct 2026
INmune Bio Is A High-Potential Opportunity, But Here's Why I'm Waiting (NASDAQ:INMB) - Seeking Alpha
Thu, 22 Oct 2026
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar - The Globe and Mail
Wed, 21 Oct 2026
INmune Bio Inc. (INMB) Targets UK MAA in Feb 2027, Approval Mid-2027 - TradingView
Wed, 21 Oct 2026
UK approval could come about six weeks earlier, Inmune Bio (INMB) says of its revised Ebstrocel plan. - Stock Titan
Wed, 21 Oct 2026
INmune Bio (INMB) Files Pre-MAA with UK MHRA for Ebstrocel Cell Therapy - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 15.6 (%) |
| Shares Short | 2,660 (K) |
| Shares Short P.Month | 2,180 (K) |
| EPS | -0.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.74 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.2 % |
| Return on Equity (ttm) | -74.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -2.18 |
| PEG Ratio | 0 |
| Price to Book value | 1.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|